All Updates

All Updates

icon
Filter
Funding
SiteOne Therapeutics awarded up to USD 15 million in grant funding
Precision Medicine
May 18, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

May 18, 2023

SiteOne Therapeutics awarded up to USD 15 million in grant funding

Funding

  • SiteOne Therapeutics, a clinical-stage biopharmaceutical company, has received a grant of up to USD 15 million from the National Institute on Drug Abuse (NIDA). This brings the total funds raised by the company to USD 34.2 million. 

  • The grant was awarded to SiteOne Therapeutics for the development of its drug candidate, STC-004, an investigational non-opioid treatment for acute and chronic pain conditions. The grant will be released in phases based on specific milestones to be completed within a two-year period. After the successful completion of these milestones, further funding will be provided for an additional three years. 

  • Montana-based SiteOne Therapeutics is a biopharmaceutical company synthesizing small molecule inhibitors to treat hypersensitivity disorders such as chronic pain, itch, and cough. The company’s candidates target voltage-gated sodium ion channels, including NaV1.7 and NaV1.8, with the company synthesizing candidates without the addiction and side effects of opioids. The company is also advancing additional candidates that will be used in the treatment of additional hypersensitivity disorders such as chronic cough and chronic ocular surface pain. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.